Cargando…

Virucidal benefits of povidone-iodine use on the ocular surface: a review

Povidone-iodine (PVI) preparations are well known for their microbicidal effect. In ophthalmology, PVI is commonly used to sterilise the ocular surface prior to surgical procedures. It is also used uncommonly as treatment for adenoviral conjunctivitis, yet the virucidal benefits of PVI have not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Edington, Magdalena, Ramaesh, Kanna, Lockington, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406023/
https://www.ncbi.nlm.nih.gov/pubmed/32818151
http://dx.doi.org/10.1136/bmjophth-2020-000509
_version_ 1783567360040370176
author Edington, Magdalena
Ramaesh, Kanna
Lockington, David
author_facet Edington, Magdalena
Ramaesh, Kanna
Lockington, David
author_sort Edington, Magdalena
collection PubMed
description Povidone-iodine (PVI) preparations are well known for their microbicidal effect. In ophthalmology, PVI is commonly used to sterilise the ocular surface prior to surgical procedures. It is also used uncommonly as treatment for adenoviral conjunctivitis, yet the virucidal benefits of PVI have not been clearly documented in existing clinical management guidelines for ocular surface conditions. The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has challenged traditional healthcare systems. The morbidity and mortality of this highly contagious disease have resulted in fatalities among healthcare workers, including ophthalmologists. The SARS-CoV-2 virus has been identified on conjunctival testing, a potential source of contagious infection which may be unrecognised in asymptomatic carriers. Concern has been raised that ocular procedures may be ‘aerosol-generating’ and the additional wearing of personal protective equipment has been recommended to protect operating theatre staff. This literature review demonstrates that PVI has a broad virucidal activity, including against coronaviruses. It is already used perioperatively as standard of ophthalmic care and has been shown clinically to be effective against adenoviruses on the ocular surface. The current surgical practice of application of 5%–10% PVI applied periocularly for 3 min seems to provide an adequate effective reduction in the patient’s ocular surface viral load. The virucidal benefits of routine PVI use should be included in ophthalmology guidelines regarding safe ocular surgery protocols.
format Online
Article
Text
id pubmed-7406023
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74060232020-08-17 Virucidal benefits of povidone-iodine use on the ocular surface: a review Edington, Magdalena Ramaesh, Kanna Lockington, David BMJ Open Ophthalmol Review Povidone-iodine (PVI) preparations are well known for their microbicidal effect. In ophthalmology, PVI is commonly used to sterilise the ocular surface prior to surgical procedures. It is also used uncommonly as treatment for adenoviral conjunctivitis, yet the virucidal benefits of PVI have not been clearly documented in existing clinical management guidelines for ocular surface conditions. The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has challenged traditional healthcare systems. The morbidity and mortality of this highly contagious disease have resulted in fatalities among healthcare workers, including ophthalmologists. The SARS-CoV-2 virus has been identified on conjunctival testing, a potential source of contagious infection which may be unrecognised in asymptomatic carriers. Concern has been raised that ocular procedures may be ‘aerosol-generating’ and the additional wearing of personal protective equipment has been recommended to protect operating theatre staff. This literature review demonstrates that PVI has a broad virucidal activity, including against coronaviruses. It is already used perioperatively as standard of ophthalmic care and has been shown clinically to be effective against adenoviruses on the ocular surface. The current surgical practice of application of 5%–10% PVI applied periocularly for 3 min seems to provide an adequate effective reduction in the patient’s ocular surface viral load. The virucidal benefits of routine PVI use should be included in ophthalmology guidelines regarding safe ocular surgery protocols. BMJ Publishing Group 2020-08-04 /pmc/articles/PMC7406023/ /pubmed/32818151 http://dx.doi.org/10.1136/bmjophth-2020-000509 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Edington, Magdalena
Ramaesh, Kanna
Lockington, David
Virucidal benefits of povidone-iodine use on the ocular surface: a review
title Virucidal benefits of povidone-iodine use on the ocular surface: a review
title_full Virucidal benefits of povidone-iodine use on the ocular surface: a review
title_fullStr Virucidal benefits of povidone-iodine use on the ocular surface: a review
title_full_unstemmed Virucidal benefits of povidone-iodine use on the ocular surface: a review
title_short Virucidal benefits of povidone-iodine use on the ocular surface: a review
title_sort virucidal benefits of povidone-iodine use on the ocular surface: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406023/
https://www.ncbi.nlm.nih.gov/pubmed/32818151
http://dx.doi.org/10.1136/bmjophth-2020-000509
work_keys_str_mv AT edingtonmagdalena virucidalbenefitsofpovidoneiodineuseontheocularsurfaceareview
AT ramaeshkanna virucidalbenefitsofpovidoneiodineuseontheocularsurfaceareview
AT lockingtondavid virucidalbenefitsofpovidoneiodineuseontheocularsurfaceareview